Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > This is what I was waiting to hear
View:
Post by gojotv! on Feb 14, 2023 1:15pm

This is what I was waiting to hear

From the ASCO press release:
"The interim data support that treatment with Photo Dynamic Therapy provides a viable treatment option for patients with BCG unresponsive CIS (+/- papillary disease) with an acceptable ongoing safety profile. Clinical trial information: NCT03945162."
Comment by gojotv! on Feb 14, 2023 1:18pm
Now that all these diverse experts agree that TLD-1433 is commercially viable, all we need is for the FDA to answer the next question: Are we gonna do this fast or slow? Come through, BTD! Then, AA, and to the moon! GLTA of us!
Comment by Lesalpes29 on Feb 15, 2023 7:14am
For me it's already slow! Hope the pace will accelerate for shareholders but more importantly the patients that need more options. When is the next financial, end of February? GL
Comment by Yajne on Feb 15, 2023 10:34am
As a 'venture' company, next financial report is May1 when they report Q4 and full year together.
Comment by enriquesuave on Feb 15, 2023 11:05am
May1st is same date as AUA meeting.  It might be epic if they show increasing efficacy from 28% 450 day CR rate.  Just IMO
Comment by Eoganacht on Feb 15, 2023 12:21pm
They usually release the annual financial statement at the end of April, so maybe we'll see an MD&A in the last week of April before the poster session on Monday, May 1. Then one month later we should see another MD&A with the 1st quarter 2023 financial statement.
Comment by enriquesuave on Feb 15, 2023 12:29pm
Most probably, we should get Update of data in MD&A with latest data up to about mid Apri perhaps, AUA will probably be data until early February IMO.  The trend will hopefully see increasing efficacy or at least a 28% CR maintained across.  FDA BTD and path to AA may come around the same time?  
Comment by Yajne on Feb 15, 2023 12:42pm
I still hope Dr Kulkarni will speak to an updated dataset when he presents tomorrow at GU-ASCO, If so, there is still tomorrow AM to issue NR with this data before the meeting, Fingers crossed! I have trouble comprehending why he might limit his presentation to the older data, especially if newest data would somewhat mitigate/dilute the effects of the initial undertreated patients.
Comment by ramrodretired on Feb 16, 2023 6:43am
What time is the good doc presenting?
Comment by Lesalpes29 on Feb 16, 2023 6:58am
The GU-ASCO cancer symposium will take place between February 16th to 18th, 2023 in San Francisco, California with the poster presented for general viewing and discussion within Poster Session B: Prostate Cancer and Urothelial Carcinoma on February 17, 2023 at 12:30 PM to 2:00 PM and 5:15 PM to 6:15 PM.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250